Navigation Links
Healthcare's First Direct Contracting Market Launches Today; Will Offer Mutually Beneficial Approach for Hospitals and Suppliers
Date:4/22/2013

n class="xn-money">$55 billion in spending, recent market analysis suggests this trend increasing. However, the self/local contracting model itself remains imperfect.  Hospitals and suppliers experience inefficiencies and redundancies, and may not have adequate access to data or to the tools necessary to make the best decisions. 

Despite efforts to change, including the increased use of technology, the industry has not made significant progress in improving the self/local contracting process.  The founders of aptitude believed that there had to be an innovative approach that combines the flexibility of direct contracting with the advantages of the time-tested national model. 

"Today, aptitude is being introduced as a contracting alternative; one that complements existing models," Mr. Kirchenbauer said. "Our early adopters --both on the supplier and the hospital side -- have been pleased with initial results. And while these organizations stand to benefit from this new approach, we feel that aptitude has the potential to lower the overall cost of providing care in our industry."

The aptitude philosophy is not a one-sided approach, nor is it an RFP generator or a reverse auction tool.  As the industry's first online contracting market, it facilitates the entire contracting process and life cycle while providing insight and value to both hospitals and suppliers. By January, 2014, aptitude expects participation from over 75 healthcare organizations and 80 product categories available for direct contracting. 

About aptitude:
As the healthcare's industry's first online direct contracting market, aptitude LLC was developed to meet the evolving demands of today's healthcare organizations. Hospitals and suppliers are intrigued by how aptitude re-imagines the local contracting model and provides the driving force for a more logical market in which h
'/>"/>

SOURCE aptitude
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Thoratec Schedules First Quarter Conference Call, Webcast
3. Watson to Host Conference Call and Webcast to Discuss First Quarter 2012 Earnings
4. CVS Caremark Corporation to Hold First Quarter 2012 Conference Call
5. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
6. Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012
7. 3SBio Inc. Schedules Unaudited First Quarter 2012 Results
8. Insmed to Host 2012 First Quarter Earnings Conference Call
9. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
10. Henry Schein to Webcast First Quarter 2012 Conference Call Tuesday, May 8, at 10:00 a.m. EDT
11. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Zafgen, Inc., a leading biopharmaceutical ... severely obese patients, today announced initial results from ... inhibitor of methionine aminopeptidase 2 (MetAP2), in patients ... genetic obesity.  These results showed improvements in body ...
(Date:1/14/2014)... 2014 InformEx, North America,s leading ... will hold the 30 th edition of its annual ... Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... fine chemical and specialty chemical companies will take part in ...
(Date:1/14/2014)... LEESBURG, Va. , Jan. 14, 2014 Animal Emergency Critical ... in Leesburg, Virginia is the first in ... hyperbaric oxygen chamber. Dr. Susan M. Barnes ... years. Dr. Barnes and husband, Dr. Cole Taylor , are ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... PRO-DEX, INC. (Nasdaq: PDEX ) invites investors and ... fiscal 2011 fourth quarter and full-year financial results. ... the internet on Wednesday, September 14, 2011 at 4:30 p.m. ... by visiting the Company,s website at www.pro-dex.com and ...
... (NASDAQ: PCYC ), a biopharmaceutical company focused ... the treatment of cancer and immune mediated diseases, today ... fourth fiscal quarter and fiscal year ended June 30, ... 12, 2011.  The company will conduct a conference call ...
Cached Medicine Technology:Pro-Dex, Inc. Announces Fiscal 2011 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast 2Pharmacyclics Announces Date of Fiscal Year End 2011 Financial Results and Conference Call 2
(Date:4/20/2014)... harmful effects in children, codeine continues to be prescribed ... UCSF Benioff Children,s Hospital San Francisco. , As reported ... include changing provider prescription behaviors to promote the use ... hydrocodone. , "Despite strong evidence against the use of ... to large numbers of them each year," said Sunitha ...
(Date:4/18/2014)... in The Gerontologist reports that ... with a decrease in anxiety about death and increases ... their lives. In particular, listening to gospel music is ... an increase in sense of control. , These associations ... and individuals of both low- and high-socioeconomic status. , ...
(Date:4/18/2014)... a brain-related discovery that could revolutionize doctors, perception ... opens up the possibility that environmental and/or genetic ... activity that the researchers have identified as helping ... Neuroscience has just published a paper about ... of psychology and his doctoral student John Gaspar, ...
(Date:4/17/2014)... chronic inflammation in non-cancerous prostate tissue may have nearly ... those with no inflammation, according to results of a ... Kimmel Cancer Center. , The link between persistent inflammation ... high-grade prostate cancer those with a Gleason score ... the most aggressive and rapidly growing prostate cancers. , ...
(Date:4/17/2014)... Experimental Biology and Medicine a multidisciplinary research ... Kenis in the Institute of Genomic Biology (IGB) ... Urbana-Champaign describe their recent work on subcellular redox ... cell functions including energy metabolism, signaling, and transcriptional ... normal cellular behavior, redox status has been recognized ...
Breaking Medicine News(10 mins):Health News:UCSF study finds codeine often prescribed to children, despite available alternatives 2Health News:Religious music brings benefit to seniors' mental health 2Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2
... , , , MANHATTAN, Kan., ... work of a K-State researcher are making headway in the effort ... Juergen Richt is a Regents Distinguished Professor at K-State,s College of ... work at K-State and with outside collaborators is revealing the characteristics ...
... Experts urge parents to get their kids, eyes checked regularly ... percent of kids aged 12 to 17 have trouble seeing ... the nearly 1,500 children in the survey, more than 25 ... though 45 percent of them wore some type of prescription ...
... , CHESTNUT HILL, Mass., Aug. 3 SkinCare ... live Artefill patient demonstration at the American Academy of Dermatology Summer ... collagen filler for the correction of smile lines and was one ... 31st. , , "Over the past several years ...
... , ALLEGAN, Mich., Aug. 3 Perrigo Company (Nasdaq: ... Pharmaceutical Industries Ltd. (Nasdaq: TEVA ) (previously Barr Laboratories ... Administration to market Triamcinolone Acetonide Nasal Spray containing a paragraph IV ... complete ANDA with a Paragraph IV certification for NASACORT AQ. The ...
... equipment alone is responsible for an increased number of ... to a study performed at San Luis Diagnostic Center ... that there was a significant increase in the number ... to digital mammography. The number of cancers detected prior ...
... in French . Heavy drinkers of ... cancer than the population at large, says a group of ... in the highest consumption category increased their risk of developing ... cancer by 50%. In all, the researchers found ...
Cached Medicine News:Health News:K-State Researcher, Collaborators Study Virulence of Pandemic H1N1 Virus; Work at K-State Would Protect Pig Industry If the Virus Jumps to Swine Populations 2Health News:Leading Boston Dermatologist Performs Live Artefill Patient Demonstration at American Academy of Dermatology Summer Meeting 2Health News:Perrigo Announces FDA Approval for Generic Version of NASACORT(R) AQ 2Health News:Perrigo Announces FDA Approval for Generic Version of NASACORT(R) AQ 3Health News:Heavy drinkers face significantly increased cancer risk 2
... Lomb PMMA Anterior Chamber Intraocular Lenses are ... in patients 60 years of age or ... removed by primary intracapsular cataract extraction; or ... a structural reason that the anterior chamber ...
... Amvisc Plus is the preferred viscoelastic ... viscoelastic that reliably works from the start ... unique, moderately cohesive profile of this viscoelastic ... vacuum forces associated with phacoemulsification remove only ...
... ENDOGEL is a sterile, non-pyrogenic solution ... is supplied in a disposable single ... fitting, delivering 0,85 ml. Sodium ... of repetitive chains of disaccharides, glucoronate, ...
... a sterile, non-pyrogenic, transparent viscoelastic preparation ... molecular weight (average molecular weight 4 ... 23 mg/mL of sodium hyaluronate 5000, ... N-acetylglucosamine and sodium glucuronate linked by ...
Medicine Products: